

ONCOLOGY DEVELOPMENT PIPELINE

PROGRAM	DESCRIPTION	DEVELOPMENT RIGHTS	DISEASE(S) UNDER INVESTIGATION	PHASE 1	PHASE 2	PHASE 3
ADCETRIS® (brentuximab vedotin) [‡]	CD30 Antibody Drug Conjugate	Global [‡]	Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma			
VECTIBIX® (panitumumab) [†]	Anti-EGFR Antibody	Japan Only	Colorectal Cancer			
LEUPLIN® (Leuprorelin acetate)	LH-RH Agonist	Japan Only	Prostate Cancer, Breast Cancer, new formulation			
NINLARO® (ixazomib)	Proteasome Inhibitor	Global	Multiple Myeloma, Amyloidosis			
TAK-228	TORC1 /TORC2 Inhibitor	Global	Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer			
PEVONEDISTAT	Nedd8-Activating Enzyme Inhibitor	Global	High-Risk Myelodysplastic Syndrome, Acute Myelogenous Leukemia			
TAK-659	SYK/FLT-3 Kinase Inhibitor	Global	Lymphoma, Acute Myelogenous Leukemia Solid Tumors			
TAK-117	PI3K Alpha Inhibitor	Global	Non-Small Cell Lung Cancer			
TAK-580	Pan-Raf Kinase Inhibitor	Global	Solid Tumors			
TAK-243	UAE Inhibitor	Global	Solid Tumors			
TAK-931	CDC7 Inhibitor	Global	Solid Tumors			
XMT-1522	HER2 Dolaflexin ADC	Ex-US, Ex-Canada*	Breast Cancer			

[‡] ADCETRIS® is co-developed by Takeda and Seattle Genetics, Inc.

[†] In-Licensed

* XMT-1522 is co-developed by Takeda and Mersana Therapeutics

All registered trademarks are the sole property of their respective owners.

Last updated 10/20/2016

OMS/ONC/15/0015(4)